Kornimate/medical-research-clean huggingface dataset:
respiratory muscle training in adults with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to investigate the effectiveness of a programme based on inspiratory and expiratory muscle training to improve respiratory muscle strength, functional capacity and avoid pulmonary complications in adults with cervical or high dorsal spinal cord injury (c5-d5) in acute phase.

the design of the study is a randomised, triple-blind clinical trial with a control group. the size of the sample will be 56 participants with cervical spinal cord injury and 56 with dorsal spinal cord injury. they will be randomized in two groups: experimental or control. the experimental group will perform combined inspiratory and expiratory muscle training as part of their rehabilitation programme during 6 weeks. the control group will continue their usual treatment. measurements will be taken at baseline, and post-intervention. the statistical analysis will be an intention-to-treat analysis, and the data processing and analysis will be carried out with the statistical package for the social sciences (spss) version 24.0 for windows (armonk, ny: ibm corp.).

Eligibility criteria:
inclusion criteria: * people diagnosed with spinal cord injury. * over 18 years of age. * time of evolution less than 6 months and at least 4 weeks after the date of injury. * level of lesion between c5 and d5 and degree of involvement a or b. in case of involvement a with partial preservation zone this should not include abdominal musculature according to the international standardised classification of the american spinal injury association. exclusion criteria: * people with chest trauma. * mechanically ventilated. * pregnant women. * any medical or psychiatric condition that could affect the ability to complete the study. * carrying a tracheostomy tube that does not tolerate occlusion. * people who can not sit upright.

Keywords: spinal cord injuries breathing exercises respiratory muscle training
stereotactic radiosurgery in patients with head and neck region tumours

Conditions: Head and Neck Cancer

Summary: the goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with h\&n tumours.

aims of the study: 1. evaluation of the efficacy of the stereotactic boost applied in patients with head and neck tumours. 2. evaluation of the safety of the stereotactic boost applied in patients with head and neck tumours. 3. evaluation of the influence of the stereotactic radiotherapy boost on blood parameters reflecting tumour response (interleukin 6 (il-6), thymidine kinase (tk), fms-related tyrosine kinase 1 (sflt-1)), and normal tissue response (c-reactive protein (crp)). in the case of beneficial findings, the stereotactic radiosurgery boost in the course of radio(chemo)therapy in patients with head and neck tumours will be able to replace traditional techniques of radiation, and radical schemes of treatment will be possible for future development.

Eligibility criteria:
inclusion criteria: 1. patients with squamous cell carcinoma (scc) or adenoid cystic carcinoma (acc) of the h\&n region qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of r2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy. 2. patients with other malignant tumours of the h\&n region (sarcomas, neuroendocrine carcinomas, differentiated carcinomas, undifferentiated carcinomas, or basaloid carcinomas) qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of r2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy. 3. patients with nonmalignant tumours of the h\&n region (tumour mixtus or paraganglioma) demanding definitive or adjuvant radiotherapy. 4. age: 18-80 years. biomedicines 2022, 10, 1484 5 of 12 5. performance status: eastern cooperative oncology group (ecog) performance status score of 0-2. 6. conscious agreement to participate in the clinical trial. exclusion criteria: 1. do not meet the inclusion criteria. 2. decompensated diabetes mellitus. 3. myocardial infarction occurred up to 6 months before. 4. pregnancy. 5. mental disorder preclusive of making a conscious agreement

Keywords: stereotactic radiotherapy radiosurgery boost head and neck cancer
diagnosis of spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis

Summary: the study is aimed to revise the current criteria for the diagnosis of spontaneous bacterial peritonitis and the decisional thresholds to start treatment. the accuracy of current diagnostic tests will be compared with that of new tests, which could potentially become more accurate reference standards. this could lead to the definition of a more accurate and effective diagnostic algorithm.


Eligibility criteria:
inclusion criteria: * patients with cirrhosis and ascites with clinical indication to carry out a diagnostic and/or therapeutic paracentesis. exclusion criteria: * etiology of ascites other than cirrhosis

Keywords: spontaneous bacterial peritonitis.
stereotactic body radiation therapy (sbrt) for tumors near the spinal cord

Conditions: Spinal Tumors

Summary: the purpose of this research study is to determine if stereotactic body radiation therapy (sbrt) is a good way to treat tumors near the spinal cord. patients will either receive a single treatment or 25 days of treatment given once-a-day, monday through friday for about 5 continuous weeks. our protocol uses life expectancy, patient preference, and tumor size to determine whether sbrt is delivered with 1 or 25 treatments. the single treatment dose is 15 gy. the 25 treatment group is 70 gy at 2.8 gy/treatment.

this protocol is a study of the use of stereotactic body radiation therapy (sbrt) for all types of primary or metastatic tumors near the spinal cord. the major goal of this study is to evaluate the efficacy and toxicity of a specific sbrt program in a prospective manner. the main outcome variables in this study are pain and neurologic function. a major issue in delivering sbrt is the number of treatment sessions. there are advantages and disadvantages to both single and multi treatment programs. in this protocol, patients are offered sbrt with either a single treatment or 25 treatment days. this study is not designed to compare different sbrt schedules. a single treatment program is more convenient and likely to relieve symptoms sooner than a multi-session program. a program with 25 treatments may produce better long-term results. our protocol uses life expectancy, patient preference, and tumor size to determine whether sbrt is delivered with 1 or 25 treatments.

Eligibility criteria:
inclusion criteria: * informed consent to participate in this protocol * patient of all ages are eligible * all tumor types are eligible * patients with prior spine radiotherapy and/or surgery to the involved area are eligible * the tumor target must be visible on mri or ct scan * stereotactic body radiation therapy (sbrt) on this protocol may produce a better outcome than conventional radiotherapy exclusion criteria: * patients who are likely to have a satisfactory outcome with surgical resection, embolization, or radiofrequency ablation without the addition of radiotherapy * tumor size, shape, or location is such that it is not reasonable to think the patient may benefit from sbrt as given in this protocol * the full extent of the tumor cannot be visualized on mri or ct scan * delaying radiotherapy for the time that it takes to start sbrt may compromise outcome compared to starting conventional radiotherapy immediately * the patient cannot be positioned reproducibly due to pain or other factors
inferior vena cava filters: analysis of a database

Conditions: Deep Vein Thrombosis, Pulmonary Embolus

Summary: in this study a retrospective analysis of patients database was performed, who underwent treatment for deep vein thrombosis in tertiary hospital by using inferior vena cava-filters

the aim of this research was to assess the cava-filter implantation frequency in a tertiary hospital with venous thromboembolism treatment center. a retrospective analysis of patient's database was performed, who underwent treatment in the tertiary clinic between 2016 - 2017. in total, 2399 patients with venous thromboembolism were hospitalized, 442 cava-filters were implanted (239 in 2016 and 203 in 2017), which accounted for 18.4% of patients with venous thromboembolism. removable cava-filters models were used in most cases (98.8%). contraindications for anticoagulation were reason for cava-filters implantation in 119 (26.9%) cases, and in 184 patients (41.6%) cava-filters were implanted due to the inefficiency of anticoagulation. 38 (8.6%) patients with deep vein thrombosis (dvt) and pulmonary embolism had pulmonary hypertension of the 2nd to 3rd degree, which caused the implantation of cava-filters . the occlusion of the inferior vena cava and cava-filters verified in 116 (26.9%) patients after cava-filters implantation, based on repeated ultrasound. the overall mortality rate in the group of patients with venous thromboembolism was 0.25% (6 patients), 5 of them (1.1%) underwent cava-filters implantation. the cause of all lethal outcomes was the progression of the underlying disease. during the next hospitalization 29 (6.5%) of implanted filters were endovascularly removed. there are 18.4% of patients with venous thromboembolism undergoing cava-filters implantation for various reasons in a tertiary hospital. at the same time, occlusion of the inferior vena cava and cava-filters in the early post implantation period is observed in 26.9%. however, without clear criteria for the differentiation of cava-filters embolism from its thrombosis, we cannot assess whether this was a complication, or if the cava-filters completed its task by preventing pulmonary embolism. thus, the validity of implanting cava filters question in terms of efficiency and safety remains unanswered, which poses the task for deep study of this problem and thorough analysis of the indications for the cava-filters implantation.

Eligibility criteria:
inclusion criteria: * anticoagulation therapy contraindicated * anticoagulation therapy ineffective * high pulmonary embolism risk (floating thrombus in proximal location) * deep vein thrombosis/pulmonary embolism together with high pulmonary hypertension(\>50 mm.hg)

Keywords: deep vein thrombosis inferior vena cava-filter pulmonary embolism
contemplative well-being apps for the workplace

Conditions: Social Behavior; Depression; Inflammation

Summary: the study will examine the use and impact of a meditation app delivered to adult workforce populations facing extreme time demands. enrollees will be randomized to either app or a wait-list group, and will be assessed in terms of job and daily functioning, well-being, and biomarkers of immune function and stress physiology, and neural structure and function prior to randomization and again at multiple time points after participants commence app engagement. in order to assess efficacy, we will examine the longitudinal changes in all measures in both the mindfulness group, compared to wait-list control group.

over the last 25 years, research on contemplative practices, a family of practices including mindfulness meditation and yoga, has advanced in domains both clinical and basic, motivated by burgeoning evidence of their efficacy for remediating psychopathology and augmenting well-being and resilience. however, much of this research has examined the effects of scheduled group interventions, delivered in-person by instructors over the course of several weeks. far less research has looked at the delivery method that is most common and arguably most sustainable for busy adults, namely, smart phone delivered contemplative applications (apps) for well-being (cwas). the proposed study will examine the use and impact of an app delivered to populations facing extreme time demands.

Eligibility criteria:
inclusion criteria: * emory healthcare and university employees, cox enterprises employees, and emory students exclusion criteria: * for students and employees in the biomarker sub-study, participants will be studied only if they pass the society of magnetic resonance imaging standardized mri screening protocol (exclusions for ferrous metal in any part of body, such as pacemakers, cochlear implants, surgical clips or metal fragments, serious medical conditions, claustrophobia)

Keywords: workplace applications anxiety burnout meditation mindfulness
impact of surgical management for relapse after conversion hepatectomy for initially unresectable colorectal liver metastasis

Conditions: Colorectal Cancer; Liver Metastases

Summary: for patients with initially unresectable colorectal liver metastasis (iu-crlm) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load. yet, few studies have focused on the assessment and management of relapse after conversion hepatectomy for iu-crlm. this study aimed to investigate the impact of surgical management for relapse after conversion hepatectomy in iu-crlm.


Eligibility criteria:
inclusion criteria: * initially unresectable colorectal liver metastasis (iu-crlm) * received conversion therapy * underwent conversion hepatectomy exclusion criteria: * the histologic type of crlm was not called adenocarcinoma * uncontrollable extrahepatic metastases, such as peritoneal, bone, brain metastasis * history of previous hepatectomy * the primary tumor was not resected or palliative resection * r1 or r2 liver resection
external validation study for risk prediction model for unsuccessful elbow flexion recovery after nerve transfer surgery in patients with brachial plexus injury

Conditions: Brachial Plexus Injury

Summary: the goal of this observational study is to validate a risk prediction model developed for unsuccessful elbow flexion recovery after nerve transfer surgery in patients with brachial plexus injury. the main question it aims to answer is how well a risk prediction model perform in a different dataset, which are patients with brachial plexus injury who underwent surgery in a different time period or a different hospital.


Eligibility criteria:
inclusion criteria: * traumatic brachial plexus injury patients underwent nerve transfer operation for re-innervation of elbow flexion at siriraj hospital between 2018 and 2020 and lerdsin general hospital between 2008 and 2022 * patients had follow-up duration at least 24 months after surgery exclusion criteria: * incomplete medical records * patients underwent free functioning muscle transfer as primary surgery for elbow flexion * obstetric brachial plexus injury * radiation-induced brachial plexopathy

Keywords: nerve transfer neurotization brachial plexus injury predictive factors external validation risk prediction model
the maximum tolerated dose of mesenchymal stem cells from umbilical cord

Conditions: Knee Osteoarthritis; Umbilical Cord Bleeding

Summary: the aim of this study was to evaluate the maximum tolerated dose of mesenchymal stem cells (mscs) from umbilical cord in the treatment of human knee oa

this is a single-centre, quadruple blined, randomized controlled trail with a total of 9 knee osteoarthrits patients as participants, who will be randomly assigned into high dose group, moderate dose group or low dose group. the participants in the high dose group will receive the treatment of high dose mscs (1×10\^8cells/3ml) anticular injection.the dose of the mscs in medium dose group is 5×10\^7cells/3ml, and the dose in the low dose group is 1×10\^7cells/3ml. unexplained local and systemic symptoms will be assessed to determine the the maximum tolerated dose of mesenchymal stem cells in anticular injection.

Eligibility criteria:
inclusion criteria: ① k / l score of 2-3; ② chronic knee pain; ③ no local or systemic infection; ④ without obvious contraindication of the joint puncture from hematology and biochemical tests; ⑤ informed consent. - exclusion criteria: ① older than 75 years old or less than 18 years old, or without full capacity for civil conduct; ② hiv, hepatitis virus or syphilis virus infection or their serology is positive; ③ bmi index is greater than 30; ④ congenital or acquired knee deformity; ⑤ pregnant or lactating women; ⑥ tumor patients; ⑦ immunodeficiency patients; ⑧ intra-articular drug injection history within 3 months; ⑨ participating in other clinical trials; ⑩ other patients who researchers believe are not eligible for inclusion such as suffering from other concomitant diseases.-

Keywords: mesenchymal stem cells knee osteoarthritis umbilical cord
angiotensin receptor blockers in aortic stenosis

Conditions: Aortic Stenosis; Aortic Valve Stenosis

Summary: this study is intended to investigate the effect of angiotensin receptor blockers (arbs) on mild-to-moderate aortic stenosis.

studies support the concept that activation of the renin-angiotensin system may be involved in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. furthermore recent studies have shown that renin-angiotensin system medication may slow down aortic stenosis progression rate and left ventricle remodeling. thus the present study is a randomized control trial to test the efficacy of the angiotensin receptor blocker (arb) to slow down aortic stenosis progression and left ventricular remodeling/dysfunction in patients with mild-to-moderate aortic stenosis.

Eligibility criteria:
inclusion criteria: * mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s) * normal left ventricular ejection fraction (i.e. ≥50%) * systolic blood pressure \>110 mmhg * diastolic blood pressure \>70 mmhg exclusion criteria: * more than mild aortic or mitral regurgitation, or mitral stenosis * current use or documented indication for renin-angiotensin system medication or aliskiren * known allergy or intolerance to angiotensin ii receptor blockers (arbs) * alzheimer, dementia or known non-compliant patient * renal dysfunction (glomerular filtration rate \<30ml/min/1.73m2) * chronic hyperkalemia * diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment * newly diagnosed (\<2 months) or poorly controlled diabetes * pre-existing obstructive coronary artery disease with ccs iii-iv angina or recent myocardial infarction (\<3 months) * pregnant or lactating women * patients unable to read, understand or sign research consent

Keywords: angiotensin ii receptor blockers left ventricular remodeling valvular heart disease aortic stenosis
oral vitamin d supplementation prevent peritoneal dialysis-related peritonitis

Conditions: Peritoneal Dialysis-associated Peritonitis; Vitamin D Deficiency

Summary: this is a multicenter randomized, placebo-controlled trial of vitamin d supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin d3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.

176 eligible patients on pd at one month after being cured from an episode of peritonitis will be enrolled and randomized into two groups, including the intervention group administered cholecalciferol (produced by xymogen company) 4000 u (2 capsules) per day, and the control group administered placebo 2 capsules per day. all participants will be followed for 24 months, or till the occurrence of death, permanently transfer to hemodialysis, loss of follow-up, or withdrawal from the study, whichever comes first. the primary outcome is the occurrence of subsequent peritonitis. the study aims to identify whether oral administration of vitamin d3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.

Eligibility criteria:
inclusion criteria: * medically stable and receiving peritoneal dialysis for \> 1 month * older than 18 years old * serum 25(oh)d \< 30ng/ml * adequate dialysis on evaluation with weekly kt/v ≥ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms exclusion criteria: * receive vitamin d2/d3 during the previous 1 month (revised time: 2023-7-11) ; * history of allergic reaction to cholecalciferol; * current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, hiv/aids; * acute systemic infection, cardiovascular disease, surgery, or trauma in the last month; * a high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months; * history of kidney transplant; * hemodialysis combined with peritoneal dialysis currently; * pregnant or breastfeeding; * not suitable enrolled assessed by researchers, including patients who could not regular follow-up

Keywords: peritoneal dialysis peritonitis cholecalciferol
comparison of o-type hybrid knife and it knife in esd

Conditions: Esophageal Cancer; Esophageal Dysplasia; Stomach Cancer; Stomach Dysplasia

Summary: by combining injection and dissection capability together, o-type hybrid knife could possibly shorten the endoscopic submucosal dissection procedure for upper gastrointestinal neoplasms.

endoscopic submucosal dissection (esd) has been accepted as an minimal invasive alternative to surgery for localized early upper gastrointestinal neoplasms recently. however, the procedure remains to be technically challenging and time consuming. many modified methods or newly developed devices were developed to simplify the procedure. a new insulated tip dissecting knife (o-type hybrid knife) has been recently developed with both injection and lateral cutting capability. the aim of this study was to investigate whether esd procedure could be shortened with this new device.

Eligibility criteria:
inclusion criteria: * gastric or esophageal adenoma or early cancer which is eligible for conventional esd indications * the patients who agreed informed consent exclusion criteria: * recent drug history of anticoagulant or antiplatelet agent within 7 days * recurrent gastric or esophageal adenoma or early cancer * pregnant or breast feeding patients.

Keywords: cancer endoscopy endoscopic submucosal dissection
patient registry: radio frequency ablation of barrett's esophagus using halo system

Conditions: Barrett's Esophagus

Summary: the purpose of this study is to provide a tool for physicians to compare outcome data related to the use of the halo ablation systems. this study is a single-center patient registry which will contribute to a framework for treatment and follow-up of patients with barrett's esophagus.


Eligibility criteria:
inclusion criteria: * candidate for ablation of barrett's esophagus with the halo ablation system (prospective) * received an ablation with the halo ablation system to treat barrett's esophagus (retrospective) * candidate agrees to proposed follow-up schedule of yearly surveillance following treatment * signs consent exclusion criteria: * has not been diagnosed with barrett's esophagus

Keywords: rfa
montelukast compared with placebo and salmeterol in exercise-induced bronchoconstriction (0476-316)

Conditions: Asthma, Exercise-Induced

Summary: to determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as exercise-induced bronchospasm), in patients who have a history of worsening asthma after exercise.


Eligibility criteria:
inclusion criteria: * physician-diagnosed exercise-induced bronchospasm exclusion criteria: * patient is, other than asthma, not in good, stable health. the primary investigator will evaluate whether there are other reasons why the patient may not participate.